Soluble Adiponectin is a New Predictor for Cardiovascular Complications in Patients with End Stage Renal Disease

Mortality due to cardiovascular complications (CVC) in patients with end stage renal disease (ESRD) is 20 fold higher than in general population. Adiponectin (ADPN) hormone from adipose tissues accumulation in serum is attributed to reduced renal clearance. The aim of this study was to investigate the possible role of ADPN as a predictor of CVC in adult patients with ESRD on hemodialysis (HD), and to evaluate the relationship between its levels and other CVC risk factors. 30 ESRD patients on regular HD with evidence of CVC (group 1), 30 ESRD patients on regular HD without evidence of CVC (group 2) and 20 age and sex matched healthy subjects (group 3) were enrolled into the study. All participants were subjected to clinical examination and laboratory investigations. Serum C-reactive protein (CRP) and ADPN concentrations were measured by ELISA. Echocardiography was performed for cardiac abnormalities estimation. The most common CVC in patients with ESRD was angina (53.33%) followed by myocardial infarction (33.33%). Patients with CVC had significant increased frequencies of risk factors (body mass index, total cholesterol, triglyceride and low density lipoprotein, and CRP in comparison with patients without CVC (P